Results 161 to 170 of about 6,682 (198)

Correction: annexin A5-DM1 protein-drug conjugate for the treatment of triple-negative breast cancer. [PDF]

Mol Biomed
Woodward A, Southard B, Chakraborty S, Bailey AO, Faria GNF, McKernan P, Razaq W, Harrison RG.   +7 more
europepmc   +1 more source

Matrix vesicle biomimetics harboring Annexin A5 and alkaline phosphatase bind to the native collagen matrix produced by mineralizing vascular smooth muscle cells. [PDF]

Biochim Biophys Acta Gen Subj, 2020
Bolean M, Izzi B, van Kerckhoven S, Bottini M, Ramos AP, Millán JL, Hoylaerts MF, Ciancaglini P.   +7 more
europepmc   +1 more source

Annexin A5 overexpression might suppress proliferation and metastasis of human uterine cervical carcinoma cells. [PDF]

Cancer Biomark, 2018
Li X, Ma W, Wang X, Ci Y, Zhao Y.
europepmc   +1 more source

Expression of annexin A5 in serum and tumor tissue of patients with colon cancer and its clinical significance. [PDF]

World J Gastroenterol, 2017
Sun CB, Zhao AY, Ji S, Han XQ, Sun ZC, Wang MC, Zheng FC.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Annexin A5 haplotypes in the antiphospholipid syndrome

Thrombosis Research, 2015
Item does not contain ...
Hiddink, L., Laat, B. de, Derksen, R.H., Groot, P.G. de, Heerde, W.L. van   +4 more
openaire   +6 more sources

Annexin A5 as a targeting agent for cancer treatment

Cancer Letters, 2022
Identifying a universal biomarker for cancer treatment remains a major challenge in cancer therapy. Extracellular exposure of phosphatidylserine (PS) is tightly regulated and is an "eat me" signal for phagocytosis in healthy cells. Although cancer cells and vasculature express high levels of externalized PS, they do not undergo apoptosis, making them a
Alexis Woodward, Gabriela N.F. Faria, Roger G. Harrison   +2 more
openaire   +2 more sources

Polymorphisms in the Annexin A5 gene influence circulating Annexin A5 levels in healthy controls

Thrombosis Research, 2012
Item does not contain ...
Hiddink, L.F., Visser, M.C.H. de, Heerde, W.L. van   +2 more
openaire   +3 more sources

Plasma Annexin A5, Anti-Annexin A5 Antibodies and Annexin A5 Polymorphism in Egyptian Female Patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome

Clinical Laboratory, 2014
Annexin A5 exhibits anticoagulant properties that appear to be defective in patients with antiphospholipid syndrome (APS) resulting in repeated thrombosis and recurrent pregnancy loss (RPL). APS occurs frequently in association with systemic lupus erythematosus (SLE).
Aya, Nasef, Mona, Ibrahim, Nermine, Riad, Somaia, Mousa   +3 more
openaire   +2 more sources

Annexin A5 as a potential marker in tumors

Clinica Chimica Acta, 2014
Annexin A5 (Anxa5) promotes pancreatic adenocarcinoma, sarcoma, tumorigenesis and progression of breast cancer and prostate cancer stem cells. It is involved with metastasis, invasion and development of squamous cell carcinoma, and facilitates nodal progression of bladder cancer and angiogenesis and progression of glioma.
Boya, Peng, Chunmei, Guo, Hongwei, Guan, Shuqing, Liu, Ming-Zhong, Sun   +4 more
openaire   +2 more sources

Annexin A5 and anti-annexin antibodies in patients with systemic lupus erythematosus

Rheumatology International, 2011
Plasma levels of annexin A5 (ANX A5) and anti-annexin A5 (aANX A5) antibodies were evaluated in 51 women with systemic lupus erythematosus (SLE). The results were compared between the total SLE group, subgroups on/without immunosuppressive therapy and the control (28 women).
Antoni, Hrycek, Paweł, Cieślik
openaire   +2 more sources